Oncotarget

Research Papers: Pathology:

Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer

Xiaozhen Liu, Yang Yang, Xiaolong Feng, Honghong Shen, Jian Liu, Xia Liu and Yun Niu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:48905-48917. https://doi.org/10.18632/oncotarget.10211

Metrics: PDF 1887 views  |   HTML 1978 views  |   ?  


Abstract

Xiaozhen Liu1, Yang Yang1, Xiaolong Feng1, Honghong Shen1, Jian Liu1, Xia Liu2 and Yun Niu1

1 Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

2 Department of Oncology, General Hospital of Tianjin Medical University, Tianjin, China

Correspondence to:

Yun Niu, email:

Keywords: androgen receptor, distant metastasis, molecular apocrine breast cancer, radiotherapy and chemotherapy, survival rate, Pathology Section

Received: May 02, 2016 Accepted: June 03, 2016 Published: June 21, 2016

Abstract

As a new subtype of breast cancer, molecular apocrine breast cancer (MABC) is estrogen receptor (ER) and progesterone receptor (PR) negative expression, but androgen receptor (AR) positive expression. The prognostic significance and clinical biological behavior of MABC have remained unclear up to now. This study aimed to analysis the distant metastasis behavior and response to adjuvant radiotherapy and chemotherapy of MABC subgroup. The report showed that there were significant differences between early and late distant metastasizing tumors with respect to Ki67, epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF) expressions by a retrospective analysis consisting of 410 invasive breast cancer patients, which included 205 MABC and 205 nonMABC cases. MABC subgroup metastasized earlier than nonMABC subgroup, and MABC showed a tendency for a higher metastasis rate in lung, liver and brain, but lower in bone. HER2-positive or VEGF-positive tumors were more inclined to develop bone metastasis within MABC subgroup. The survival rate was superior for patients undergone both adjuvant radiotherapy and chemotherapy than those undergone chemotherapy alone in nonMABC subgroup, but there was no significant difference in MABC subgroup. Our data suggested that MABC subgroup seemed to develop distant metastasis earlier than nonMABC subgroup, and patients with MABC indicated poor prognosis. This study might also provide a foundation for helping patients receive reasonable treatments according to molecular subtype.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10211